πŸ‡ΊπŸ‡Έ FDA
Patent

US 11203574

Human plasma kallikrein inhibitors

granted A61PA61P1/02A61P1/04

Quick answer

US patent 11203574 (Human plasma kallikrein inhibitors) held by BioCryst Pharmaceuticals, Inc. expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BioCryst Pharmaceuticals, Inc.
Grant date
Tue Dec 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
22
CPC classes
A61P, A61P1/02, A61P1/04, A61P11/04, A61P13/02